PATENT CLAIM ANALYSIS

Application Number: 16304564
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-06
Patent Classification: ["424", "232100"]

Abstract:
Methods utilizing vaccinia virus with mutations in E3L to infect and cause lysis of cancer cells with less than normal protein levels of RIP3 and/or DAI. Further, the disclosed vaccinia viruses with mutations in E3L cannot replicate well in cells with normal expression or upregulation of RIP3, DAI, and/or MLKL.

Claim (Index 21):
The composition of  claim 20 , wherein said at least one chemotherapeutic agent is selected from the group consisting of actinomycin, all-trans retinoic acid, azacitidine, azathioprine, bleomycin, bortezomib, carboplatin, capecitabine, cisplatin, chlorambucil, cyclophosphamide, cytarabine, daunorubicin, docetaxel, doxifluridine, doxoruhicin, epirubicin, epothil one, etoposide, fluorouracil, gemcitabine, hydroxyurea, idarubicin, imatinib, irinotecan, mechlorethamine, mercaptopurine, methotrexate, mitoxantrone, oxaliplatin, paclitaxel, pemetrexed, teniposide, tioguanine, topotecan, valrubicin, vinblastine, vincristine, vindesine, and vinorelbine.

Metadata:
- Claim Count in Document: 44.0
- Percentile: 98.0
- Lexical Diversity: 1.47368
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14166606', '15758689', '13383396', '13060028', '13147842']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7690005663301324
- 35 USC 102 Novelty (BERT): 0.5161191940846167
- Combined Prediction Score: 0.7437124291055808
- Mean Citation Score: 256.83684600000004
- Max Citation Score: 270.8731
- Similarity Product: 155.39374903171063

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test